Our Impact

Leading the world in controlling and eliminating cervical cancer through screening and vaccination

IMPACT OF THE ACPCC

How are we making a difference?

ACPCC has a proven track record in delivering population health outcomes that make a difference. In particular, we have been at the forefront of preventing and controlling cervical cancer through screening programs and HPV vaccines.

Over the years, ACPCC has been instrumental in advising and informing public health policy around cervical screening, HPV screening and HPV vaccination. 

Key examples of our impact:

  • The creation of Australia’s first Pap test registry
  • Working for the Australian Department of Health to create and run the country’s first register for the HPV vaccination program
  • Playing a key role in the provision of evidence and support in the 2017 changes to the National Cervical Screening Program, transitioning from 2-yearly Pap tests to 5-yearly HPV tests
  • Becoming Australia’s first accredited lab for processing HPV self-collection tests

Due to the efforts and achievements of the Australian Centre for the Prevention of Cervical Cancer, Australia is well on track to eliminate cervical cancer as a public health problem by 2035, becoming the first country in the world to do so.

ACPCC often features in the news. Here is a collection of the latest news stories either featuring ACPCC or of interest to our organisation. 

The team at ACPCC is well published. We maintain an extensive list of ACPCC author publications along with other reports and articles. 

Consider a donation to the ACPCC, and support our vital work toward the elimination of cervical cancer.

ACPCC works with Australian and international partners to achieve the World Health Organization’s goal of eliminating cervical cancer as a public health problem.

ACPCC has worked  to support population health programs around the world in countries like New Zealand, Malaysia, India, Vanuatu, and PNG.  Our ongoing projects in this region are working towards the WHO target to eliminate cervical cancer by 2030.

Compass is a randomised controlled trial to compare 2.5-yearly cytology-based cervical screening with 5-yearly primary HPV screening in Australian women aged 25-69.

Latest News

Canberra, Australia – In a landmark event, the Australian Centre for the Prevention of Cervical Cancer (ACPCC) has signed a Memorandum of Understanding (MOU)…

Get in touch

To find out more about what we do or how we can work together, please get in touch. 

Search our site